Alere Company Profile (NYSE:ALR)

About Alere (NYSE:ALR)

Alere logoAlere Inc. is a provider of health information through diagnostic tests. The Company's segments include professional diagnostics, consumer diagnostics, and corporate and other. The professional diagnostics segment includes an array of diagnostic test products and other in vitro diagnostic tests marketed to medical professionals and laboratories for detection of diseases and conditions within its areas of focus. The consumer diagnostics segment consists primarily of manufacturing operations related to its role as the exclusive manufacturer of products for SPD Swiss Precision Diagnostics (SPD), its joint venture with The Procter & Gamble Company (P&G). The Company's professional diagnostic solutions allow patients and their healthcare providers to work together to manage patients' conditions over the continuum of care, from the hospital to home. The Company offers lines of drugs-of-abuse tests, reagent systems and laboratory testing options.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Health Care Supplies
  • Symbol: NYSE:ALR
  • CUSIP: 01449J10
  • Web:
  • Market Cap: $4.25 billion
  • Outstanding Shares: 87,001,000
Average Prices:
  • 50 Day Moving Avg: $47.66
  • 200 Day Moving Avg: $41.11
  • 52 Week Range: $31.47 - $49.53
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 22.92
  • P/E Growth: 2.34
Sales & Book Value:
  • Annual Revenue: $2.39 billion
  • Price / Sales: 1.78
  • Book Value: $16.56 per share
  • Price / Book: 2.95
  • EBIDTA: $317.98 million
  • Net Margins: -1.64%
  • Return on Equity: 8.01%
  • Return on Assets: 1.97%
  • Debt-to-Equity Ratio: 2.02%
  • Current Ratio: 2.14%
  • Quick Ratio: 1.65%
  • Average Volume: 1.70 million shs.
  • Beta: 0.6
  • Short Ratio: 3.19

Frequently Asked Questions for Alere (NYSE:ALR)

What is Alere's stock symbol?

Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."

How were Alere's earnings last quarter?

Alere Inc (NYSE:ALR) announced its quarterly earnings data on Friday, November, 4th. The company reported $0.19 EPS for the quarter, missing the Zacks' consensus estimate of $0.54 by $0.35. The firm earned $582 million during the quarter, compared to analyst estimates of $605.50 million. Alere had a positive return on equity of 8.01% and a negative net margin of 1.64%. Alere's revenue for the quarter was down 3.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.10) earnings per share. View Alere's Earnings History.

Where is Alere's stock going? Where will Alere's stock price be in 2017?

6 equities research analysts have issued 12-month price objectives for Alere's shares. Their forecasts range from $42.00 to $56.00. On average, they anticipate Alere's share price to reach $49.60 in the next twelve months. View Analyst Ratings for Alere.

What are analysts saying about Alere stock?

Here are some recent quotes from research analysts about Alere stock:

  • 1. BTIG Research analysts commented, "Continued Growth in Infectious Disease Business Yesterday, Alere filed its preliminary unaudited 10-K and proxy statements following review of matters in South Korea and Japan, and expects to file their Form 10-K by June 15th, 2017. The preliminary financial statements included 4Q16 and FY2016 results, as well as re- statements for revenue recognition during 2014, 2015, and 2016. Topline preliminary 1Q17 financial results were also provided. The filing of the proxy indicates a decoupling process versus the 10-K filing, allowing the shareholder meeting to likely occur between mid-to-late July. The company must resolve outstanding accounting issues and file the 10K by June 15 th or face another negotiation with the creditors and bond holders. We remain Neutral as we continue to think that the deal with Abbott (ABT, Buy, $50PT) will close at the stated terms of $51 per share later this year." (5/24/2017)
  • 2. According to Zacks Investment Research, "Alere Inc., formerly known as Inverness Medical Innovations, Inc., provides products and services, which focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts. " (4/19/2017)

Are investors shorting Alere?

Alere saw a drop in short interest in the month of May. As of May 15th, there was short interest totalling 1,289,823 shares, a drop of 31.0% from the April 28th total of 1,869,308 shares. Based on an average trading volume of 2,382,140 shares, the days-to-cover ratio is presently 0.5 days. Approximately 1.5% of the company's stock are sold short.

Who are some of Alere's key competitors?

Who owns Alere stock?

Alere's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (0.00%), Iridian Asset Management LLC CT (0.00%), Dimensional Fund Advisors LP (0.00%), Diamond Hill Capital Management Inc. (2.79%), USS Investment Management Ltd (0.00%) and First Eagle Investment Management LLC (1.58%). Company insiders that own Alere stock include James F Hinrichs, John Bridgen, Mark Gladwell, Melissa Guerdan, Robert Bernard Hargadon and Sanjay Malkani. View Institutional Ownership Trends for Alere.

Who sold Alere stock? Who is selling Alere stock?

Alere's stock was sold by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, First Eagle Investment Management LLC, Cowen Group Inc., Jennison Associates LLC, York Capital Management Global Advisors LLC, Gabelli Funds LLC, Stonepine Capital Management LLC and Everett Capital Advisors UK LLP. View Insider Buying and Selling for Alere.

Who bought Alere stock? Who is buying Alere stock?

Alere's stock was bought by a variety of institutional investors in the last quarter, including Litespeed Management L.L.C., Renaissance Technologies LLC, Vanguard Group Inc., Laurion Capital Management LP, First Trust Advisors LP, Janus Capital Management LLC, Cornerstone Capital Management Holdings LLC. and Jane Street Group LLC. Company insiders that have bought Alere stock in the last two years include James F Hinrichs and Robert Bernard Hargadon. View Insider Buying and Selling for Alere.

How do I buy Alere stock?

Shares of Alere can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Alere stock cost?

One share of Alere stock can currently be purchased for approximately $48.82.

Analyst Ratings

Consensus Ratings for Alere (NYSE:ALR) (?)
Ratings Breakdown: 4 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $49.60 (1.60% upside)

Analysts' Ratings History for Alere (NYSE:ALR)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/24/2017BTIG ResearchReiterated RatingHoldLowView Rating Details
5/22/2017Canaccord GenuityReiterated RatingBuy$51.00LowView Rating Details
5/15/2017Craig HallumDowngradeBuy -> HoldLowView Rating Details
4/17/2017Jefferies Group LLCLower Price TargetHold$56.00 -> $51.00HighView Rating Details
11/4/2016Goldman Sachs Group IncLower Price TargetNeutral$45.00 -> $42.00N/AView Rating Details
7/12/2016Leerink SwannReiterated RatingBuy$56.00N/AView Rating Details
2/2/2016Raymond James Financial, Inc.DowngradeOutperform -> Market PerformN/AView Rating Details
11/5/2015WedbushLower Price TargetNeutral$43.00 -> $39.00N/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Alere (NYSE:ALR)
Earnings by Quarter for Alere (NYSE:ALR)
Earnings History by Quarter for Alere (NYSE:ALR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016Q3 16$0.54$0.19$605.50 million$582.00 millionViewN/AView Earnings Details
9/6/2016Q216$0.58($0.46)$621.95 million$611.10 millionViewN/AView Earnings Details
8/17/2016Q116$0.56($0.18)$578.00 millionViewN/AView Earnings Details
8/8/2016Q415$0.58($0.28)$662.04 million$623.00 millionViewN/AView Earnings Details
11/4/2015Q315$0.55$0.49$646.29 million$602.00 millionViewN/AView Earnings Details
8/4/2015Q215$0.53$0.49$625.67 million$629.00 millionViewN/AView Earnings Details
5/5/2015Q115$0.49$0.57$612.93 million$610.40 millionViewN/AView Earnings Details
2/10/2015Q414$0.63$0.61$698.56 million$666.90 millionViewN/AView Earnings Details
10/28/2014Q314$0.52$0.48$743.30 million$736.20 millionViewN/AView Earnings Details
8/4/2014Q214$0.58$0.43$747.55 million$738.30 millionViewN/AView Earnings Details
4/29/2014Q114$0.55$0.55$738.70 million$716.60 millionViewN/AView Earnings Details
2/6/2014Q413$0.56$0.62$770.70 million$772.30 millionViewN/AView Earnings Details
10/29/2013Q313$0.53$0.59$737.66 million$753.90 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.48$0.64$720.24 million$764.00 millionViewN/AView Earnings Details
5/9/2013Q1 2013$0.51$0.53$727.66 million$739.20 millionViewN/AView Earnings Details
2/15/2013Q4 2012$0.57$0.55$714.75 million$755.80 millionViewN/AView Earnings Details
11/8/2012Q312$0.53$0.43$690.76 million$691.40 millionViewN/AView Earnings Details
8/8/2012$0.53($0.23)ViewN/AView Earnings Details
4/30/2012$0.67$0.77ViewN/AView Earnings Details
2/8/2012$0.71$0.74ViewN/AView Earnings Details
10/26/2011$0.57$0.67ViewN/AView Earnings Details
7/27/2011$0.58$0.46ViewN/AView Earnings Details
4/27/2011$0.61$0.61ViewN/AView Earnings Details
2/17/2011$0.66$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alere (NYSE:ALR)
Current Year EPS Consensus Estimate: $2.09 EPS
Next Year EPS Consensus Estimate: $2.13 EPS


Dividend History for Alere (NYSE:ALR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Alere (NYSE:ALR)
Insider Ownership Percentage: 3.66%
Institutional Ownership Percentage: 91.82%
Insider Trades by Quarter for Alere (NYSE:ALR)
Institutional Ownership by Quarter for Alere (NYSE:ALR)
Insider Trades by Quarter for Alere (NYSE:ALR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/1/2016Melissa GuerdanSVPSell2,500$54.00$135,000.00View SEC Filing  
11/13/2015Robert Bernard HargadonSVPBuy1,000$38.99$38,990.00View SEC Filing  
11/12/2015James F HinrichsCFOBuy10,000$39.97$399,700.00View SEC Filing  
9/3/2015Mark GladwellVPSell2,651$52.27$138,567.77View SEC Filing  
9/3/2015Melissa GuerdanSVPSell5,135$52.00$267,020.00View SEC Filing  
9/1/2015Melissa GuerdanSVPSell5,000$50.48$252,400.00View SEC Filing  
8/31/2015Mark GladwellVPSell27,513$52.23$1,437,003.99View SEC Filing  
8/14/2015Sanjay MalkaniInsiderSell31,460$54.60$1,717,716.00View SEC Filing  
6/8/2015Sanjay MalkaniInsiderSell24,331$50.87$1,237,717.97View SEC Filing  
6/4/2015Sanjay MalkaniInsiderSell15,669$52.18$817,608.42View SEC Filing  
6/1/2015John BridgenSVPSell7,500$51.19$383,925.00View SEC Filing  
4/6/2015Melissa GuerdanSVPSell2,500$50.00$125,000.00View SEC Filing  
3/23/2015Melissa GuerdanSVPSell13,476$48.35$651,564.60View SEC Filing  
3/17/2015John BridgenSVPSell25,000$48.53$1,213,250.00View SEC Filing  
3/16/2015Carla FlakneCAOSell8,500$48.99$416,415.00View SEC Filing  
1/16/2015Carla FlakneCAOSell10,000$42.45$424,500.00View SEC Filing  
12/24/2014Don DudekDirectorBuy40,000$0.01$500.00
12/11/2014John BridgenSVPSell50,000$37.07$1,853,500.00View SEC Filing  
8/15/2014Dave TeitelCFOSell10,000$35.07$350,700.00View SEC Filing  
8/15/2013Dave TeitelCFOSell10,000$31.73$317,300.00View SEC Filing  
8/5/2013Michael Lester CottonInsiderSell12,500$33.82$422,750.00View SEC Filing  
5/31/2013Michael Lester CottonInsiderSell8,750$25.86$226,275.00View SEC Filing  
3/5/2013John QuelchDirectorSell20,220$23.49$474,967.80View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Alere (NYSE:ALR)
Latest Headlines for Alere (NYSE:ALR)
DateHeadline logoAlere's (ALR) Hold Rating Reiterated at BTIG Research - May 24 at 3:56 PM logoAlere Sees Wider Loss From Cont. Ops, Lower Revenue In Q4 - Quick Facts - May 24 at 3:28 PM logoAlere (ALR) Offers Prelim. Q1 Results and Update on Form 10-K - May 24 at 3:28 PM logoAlere's (ALR) Buy Rating Reiterated at Canaccord Genuity - May 22 at 4:28 PM logoAlere (ALR) Offers Prelim. Q1 Results and Update on Form 10-K - - May 22 at 3:30 PM logoAlere Announces Update on Form 10-K and Provides Preliminary Unaudited Financial Results - May 22 at 3:30 PM logoAlere Q4 top line off 3%; loss/share of $1.41; shares up 2% on resolution accounting errors in South Korea - May 22 at 10:10 AM logoAre Options Traders Betting on a Big Move in Alere (ALR) Stock? - May 18 at 12:20 PM logoGreenlight Capital Quadrupled General Motors Stake in Activist Push - May 16 at 3:30 PM logoAlere's (ALR) Neutral Rating Reaffirmed at BTIG Research - May 15 at 1:56 PM logoAlere Inc (ALR) Given Average Recommendation of "Hold" by Brokerages - May 15 at 11:22 AM logoAlere Inc (ALR) Downgraded by Craig Hallum - May 15 at 10:34 AM logoAlere Inc. Announces Successful Completion of Consent Solicitations for Alere Inc.'s Notes - May 8 at 8:27 PM logo Brokerages Anticipate Alere Inc (ALR) Will Post Earnings of $0.34 Per Share - May 5 at 8:22 PM logoAlere Inc. Announces Modifications of Consent Solicitations for Alere Inc.'s Notes - May 4 at 3:32 PM logoPositive News Coverage Very Likely to Impact Alere (ALR) Share Price - May 3 at 10:26 AM logoAlere Inc. Announces Commencement of Consent Solicitations for Alere Inc.'s Notes - May 1 at 9:43 AM logoAlere (ALR) Earning Somewhat Favorable Press Coverage, Report Finds - April 28 at 11:04 AM logoFavorable News Coverage Likely to Affect Alere (ALR) Share Price - April 25 at 2:31 PM logoAlere Launches the Alere™ Malaria Ag P.f, the First-Ever Rapid Test to Screen Malaria Infection in Asymptomatic Individuals - April 25 at 8:43 AM logoAlere (ALR) Getting Somewhat Negative Press Coverage, Analysis Shows - April 21 at 10:08 AM logoAbbott CEO Upbeat Despite Ongoing Merger Headaches - April 19 at 8:30 PM logoAlere Inc (ALR) Stock Rating Lowered by Zacks Investment Research - April 19 at 7:29 PM logoAlere Inc. (ALR) Jumped After Amended Merger Agreement - April 19 at 3:27 PM logoAbbott and Alere: It's an M&A Miracle - April 19 at 3:27 PM logoAlere Stock Surging on Latest Abbott Agreement - April 19 at 3:27 PM logoAlere (ALR) Shows Strength: Stock Adds 15.9% in Session - Yahoo Finance - April 19 at 7:21 AM logoAlere Inc (ALR) Receives Consensus Rating of "Buy" from Brokerages - April 18 at 12:26 PM logoAlere (ALR) Earning Positive News Coverage, Report Shows - April 18 at 11:04 AM logoAlere Inc (ALR) Stock Rating Reaffirmed by Canaccord Genuity - April 17 at 4:38 PM logoAbbott (ABT) to Acquire Alere (ALR) for $51/Share in Amended Agreement - - April 17 at 3:27 PM logoBUZZ-U.S. STOCKS ON THE MOVE-Incyte, MoneyGram, Alere, OncoMed - Nasdaq - April 17 at 3:27 PM logoWill Abbott, Alere Make It To Altar In New Merger Deal? - April 17 at 3:27 PM logoAlere Inc (ALR) Rating Reiterated by Jefferies Group LLC - April 17 at 2:16 PM logoAlere Inc. Shares Surge After Renewed Commitment From Abbott Laboratories - April 17 at 1:37 PM logoAbbott (ABT) to Acquire Alere (ALR) for $51/Share in Amended Agreement - April 17 at 7:17 AM logo Brokerages Expect Alere Inc (ALR) Will Post Quarterly Sales of $586.46 Million - April 16 at 8:02 AM logo[$$] Abbott, Alere Advance Contentious Merger With Reduced Price - April 15 at 11:22 AM logoAlere (ALR) Earning Somewhat Negative Press Coverage, Report Shows - April 15 at 10:55 AM logo Brokerages Anticipate Alere Inc (ALR) to Announce $0.45 Earnings Per Share - April 14 at 10:18 PM logoAbbott Agrees To Buy Alere At Lower Price - April 14 at 11:38 AM logoAbbott and Alere move forward with merger at lower price - April 14 at 11:38 AM logoAbbott and Alere Agree to Play Nice With $5.3 Billion Deal - April 14 at 11:38 AM logoAbbott and Alere Amend Terms of Merger Agreement - April 14 at 11:38 AM logoAbbott to slash price it will pay for Alere by nearly 9% to about $5.3 billion - April 14 at 11:38 AM logoAbbott agrees to buy Alere at lower price from earlier offer - April 14 at 11:38 AM logoAlere agrees to discounted $5.3B merger with Abbott, ending legal battle - April 14 at 11:38 AM logo[$$] Abbott, Alere Advance Merger With Reduced Price - April 14 at 11:38 AM logoAbbott finalizes discounted deal with Alere, ending legal battle - April 14 at 11:38 AM logoAbbott Labs to buy Alere for $51/share in amended deal - April 14 at 9:46 AM



Alere (ALR) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff